The Board of Directors in its meeting held on 10.12.2009 has approved the following matters:
1. Increase in the Authorised Share Capital of the Company from
30 crores to
2. Issue of 15,00,000 equity shares and 30,00,000 equity warrants, carrying an option to the holder of such warrants to subscribe to one equity share of
10/- for every warrant held, within 18 months from the date of allotment of the warrants at the price to be fixed as per SEBI Regulations to the Promoters / Promoter group companies on the Preferential basis.
3. Convening of Extra-ordinary General Meeting on 09.01.2010.
4. Commencement of trial production of Iso-butyl Benzene, which is basic raw material for Ibuprofen.